UK Investigates Ozempic, Zepbound Over Pancreas problem Reports

health regulators launch investigation into Ozempic and Zepbound following reports of severe pancreas issues. Learn about the potential risks and genetic factors.">

British health authorities have launched an investigation into popular weight-loss and diabetes drugs like Ozempic and Zepbound after hundreds reported severe pancreas-related issues the BBC.The Medicines and Healthcare products Regulatory Agency and Genomics England are managing the investigation, which includes up to 10 fatalities.

The UK government is urging affected individuals to come forward, particularly to explore potential genetic links to these adverse reactions. While a direct causal link between the drugs and pancreas damage remains unconfirmed, the investigation aims to assess the scope and nature of these reports UK Gov.

Why the Investigation into Ozempic and Other GLP-1 Drugs?

The core concern stems from a notable increase in reports of acute and chronic pancreatitis among users of GPL-1 (glucagon-like peptide-1) receptor agonists. These drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, mimic the natural GLP-1 hormone, regulating blood sugar and appetite Science Alert. They are commonly prescribed for type 2 diabetes and weight management.

Did You Know? The UK’s Yellow Card scheme is the official system for reporting suspected side effects or other safety concerns involving medicines and medical devices.

Almost 400 reports of acute pancreatitis have surfaced among users of these drugs, with nearly half linked to Mounjaro, a tirzepatide-based medication